Efficacy Observation Of Entecavir Combined With Fuzheng Huayu Capsule In The Treatment Of Hepatitis B Cirrhosis

Objective:To compare the efficacy of Entecavir(ETV)combined with Fuzheng Huayu Capsule(FHC)and ETV alone in the treatment of hepatitis B cirrhosis.We try to scientifically and objectively evaluate the efficacy and safety of the combination of the two drugs,and to provide a useful reference for clinical treatment of hepatitis B cirrhosis.Methods:Prospective case-control study was used.Totally 155 cases of hepatitis B liver cirrhosis patients who were selected from January 2016 to December 2017 were assigned to the control group(n=77)and the treatment group(n=78)by random figure table.Patients in the control group were treated with ETV alone,while those in the treatment group additionally took FHC.The changes of liver function indices,HBV DNA negative conversion rate,liver fibrosis indices(HA,PC-III,IV-C and LN),liver stiffness measurement(LSM)and ultrasound imaging indices(portal vein diameter,spleen length and spleen thickness)were compared between the two groups after 48 and 72 weeks of treatment..Results:(1)Liver function indices:At week 48,ALT,AST and TBIL levels in the two groups were all significantly lower than before treatment(p<0.05),the treatment group was better than the control group(p<0.05).There was no statistical difference between the two groups at week 72(p>0.05).(2)HBV DNA negative conversion rate:There was no statistical difference between the two groups at week 48(p>0.05),while there was a statistical difference between the two groups at week 72(?2=4.141,p<0.05).(3)Liver fibrosis indices:At week 48,HA,PC-?,?-C and LN in the two groups were significantly lower than before treatment(p<0.05),but there was no statistical difference between the two groups(p>0.05).At week 72,they were further improved than week 48(p<0.05),and also had a statistical difference between the two groups(p<0.05).(4)LSM:At week 48,the LSM in the two groups decreased significantly compared with that before treatment(p<0.05),but there was no statistical difference between the two groups(p>0.05).At week 72,it decreased more obviously of the treatment group,compared with it at week 48 and the control group at week 72(p<0.05).(5)Ultrasound imaging indices:At week 48,portal vein diameter,spleen length and spleen thickness in the treatment group decreased significantly than before treatment(p<0.05),while there was no statistical difference of the control group than before treatment(p>0.05),was also no statistical difference between the two groups(p>0.05).At week 72,they decreased more obviously of the treatment group,compared with it at week 48 and the control group at week 72(p<0.05).(6)Clinical comprehensive efficacy:After 48 and 72 weeks of treatment,the total effective rate of the treatment group was 89.74%(70/78)and 93.59%(73/78),higher than the control group[77.92%(60/77)and 83.12%(64/77)](?2=4.003,4.141,p<0.05).(7)In the course of the experiment,there was no obvious adverse reactions occurred in the two groups.Conclusions:(1)The effect of ETV combined with Fuzheng Huayu Capsule in the treatment of hepatitis B cirrhosis is better than ETV alone.It can significantly improve the degree of liver inflammation and fibrosis;reduce LSM,portal vein diameter,spleen length and spleen thickness,and delay the progress of disease.(2)The longer the course of combined medication treatment,the more obvious the effect,and the safety was good.It is worthy of clinical application and promotion.